ClinicalTrials.gg
CompletedNCT07050875Updated Jan 27, 2026

Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting

An interventional study of ABLE Exoskeleton in Acquired Brain Injury (Including Stroke), sponsored by ABLE Human Motion S.L.. Completed at 3 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Brain Injuries with a site in Spain — 11 open to participants now, 13 under way, none of them phase 3. Brain Injuries · Spain.

Enrollment
27th of 30
14 · median 30
Started
2025
with 6 others
No phase
27 of 43
8 open now
Registered
37th of 43
by date
Lead sponsor
2 of 43
ABLE Human Motion S.L.

Among the 43 studies in Brain Injuries with a site in Spain, this one is the 27th largest by enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2025, is one of 27 with no phase, and was the 37th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

11 of the 43 studies in Brain Injuries with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Brain Injuries with a site in Spain, or all of them as a file.
02

Study summary

The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting.

The secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.

Read the detailed description

This is a pre-post, multicenter, quasi-experimental study with an estimated duration of 17 weeks. The study will be conducted at the Centro Europeo de Neurociencias (CEN), Cefine Neurología (CEFINE), and Fundación Step by Step Foundation, where a minimum of 15 participants (5 per center) are expected to be recruited within a period of 8 weeks.

After obtaining informed consent, through the Patient Information Sheet and the Informed Consent Form, the selection of the participants will be carried out to determine their inclusion in the study. Subjects who do not meet all the inclusion and exclusion criteria during the screening visit will be excluded from the study. At the latest, one week after the screening visit, the participants will undergo a baseline assessment without the medical device.

Participants will undergo a 10-session training program with the ABLE Exoskeleton device for a maximum duration of 6 weeks. Sessions will be conducted 2 times per week. Each session will last approximately 60 minutes. During the training period, session data will be taken to assess the safety and clinical performance of the device. At the latest, one week after the last training session, a post-training assessment will be performed. Finally, two weeks after the last training session, a follow-up assessment will be made to the participants via a telephone call to review any adverse events (AE) reported between the end of the training and the follow-up.

03

Conditions studied

  • Acquired Brain Injury (Including Stroke)

Browse trials for

Keywords

  • Gait training
  • Wearable exoskeleton
  • Acquired Brain Injury
  • Lower-limb exoskeleton
  • Multicenter
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years old
  • Diagnosed with acquired brain injury (ABI)
  • Currently undergoing outpatient physical therapy treatment in one of the investigation sites
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • Significant osteoporosis that may increase the risk of fracture
  • Unresolved fractures in the pelvis or extremities, or history of fragility fractures in the lower extremities in the last 2 years
  • Spinal instability (or spinal orthoses, unless authorized by a physician)
  • Severe spasticity: Level 4 on the Modified Ashworth Scale
  • Orthostatic hypotension. Inability to tolerate a minimum of 10 minutes standing
  • Uncontrolled autonomic dysreflexia
  • Medical instability
  • Unstable cardiovascular system (CVS), hemodynamic instability, untreated hypertension (SBP>140, DBP>90 mmHg), unresolved deep venous thrombosis (DVT), uncontrolled autonomic dysreflexia
  • Serious comorbidities, including any condition that a physician deems inappropriate for use of the ABLE Exoskeleton or to complete participation in the study
  • Skin integrity problems on the contact surfaces of the device or that would prevent sitting
  • Grade I or higher on EPUAP (European Pressure Ulcer Advisory Panel, 2019) on areas that will be in contact with the exoskeleton
  • Colostomy
  • Anthropometric measurements outside the values compatible with ABLE Exoskeleton. In particular, height not between 1.5-1.9 m, or weight over 100 kg
  • Anatomical constraints (such as leg length differences, users unable to position themselves inside the device) that are incompatible with the device
  • Restrictions in range of motion that prevent normal gait from being achieved or preventing the completion of a normal transition from sitting to standing or standing to sitting
  • Heterotopic ossification
  • Known pregnancy or breastfeeding
  • Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures
  • Requires assisted ventilation.
  • Scoliosis >40-50º Cobb angle.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Gait training with exoskeleton

    Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.

    Device: ABLE Exoskeleton

Interventions

  • DeviceABLE Exoskeleton

    Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.

06

What researchers measure

Primary outcomes

  1. Number and type of device-related Adverse Events

    To assess safety, the number of Severe Adverse Events (SAE), Adverse Events (AE) and drop-outs due to the device will be assessed and reported.

    Time frame: From baseline to follow-up (up to 2 weeks after end of intervention)

  2. Level of Assistance (LoA) to don/doff the device

    Level of Assistance (LoA) to don/doff the device will be measured in every session. The level of assistance will be measured using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. Different assistance levels are defined taking into account the degree of participation of both the participant and the therapist on performing the activity.

    Time frame: Up to 6 weeks

  3. Time taken to don/doff the device

    The time taken to don/doff the device will be measured in every session. Time will be measured in minutes and seconds for each activity. Donning time will start from the moment the participant is ready to transfer into the device until all the straps and clips are correctly tightened. Doffing time will start from the moment the participant starts taking off the device until they have completely removed it.

    Time frame: Up to 6 weeks

  4. Number of steps walked

    In each gait training session, the number of steps taken (step count) with the device will be automatically measured and registered by the device

    Time frame: Up to 6 weeks

  5. Distance walked

    In each gait training session, the distance walked (in meters) with the device will be automatically measured and registered by the device

    Time frame: Up to 6 weeks

  6. Time spent upright and time spent walking

    In each gait training session, the time spent upright (in minutes) and the time spent walking (in minutes) with the device will be automatically measured and registered by the device

    Time frame: Up to 6 weeks

  7. Number of therapists assisting the session

    In each gait training session, the number of therapists assisting will be recorded

    Time frame: Up to 6 weeks

  8. Level of Assistance (LoA) during training

    Four therapy activity tasks will be attempted every session by the participant. The therapist will record the level of assistance required to complete each task during the session, using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. The tasks are the following: sit-to-stand, walk 10 meters, turn 180 degrees, and stand-to-sit.

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Lower extremity muscle strenght

    The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity)

    Time frame: At baseline (day 0) and post-training (up to 7 weeks)

  2. Functional Ambulation Category (FAC)

    The patient's walking ability is evaluated with the Functional Ambulation Category (FAC) scale. It has 6 categories, from 0 (patient who is not able to walk) to 5 (independent patient who does not need any help to walk)

    Time frame: At baseline(day 0) and post-training (up to 7 weeks)

  3. 10-Meter Walking Test (10MWT)

    The 10-Meter Walking Test (10MWT) test measures the time a person needs to walk 10 meters. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.

    Time frame: At baseline(day 0) and post-training (up to 7 weeks)

  4. 6-Minute Walk Test (6MWT)

    The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be assessed at baseline and at the end of the gait training program without the device to assess the change in the walking function after the training

    Time frame: At baseline (day 0) and post-training (up to 7 weeks)

  5. Timed Up and Go (TUG)

    The Timed Up-and-Go Test (TUG) measures the time it takes a person to get up from a chair, walk 3 meters, turn around, and sit down again. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.

    Time frame: At baseline (day 0) and post-training (up to 7 weeks)

  6. Trunk Impairment Scale (TIS)

    The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance).

    Time frame: At baseline (day 0) and post-training (up to 7 weeks)

  7. Berg Balance Scale (BBS)

    The Berg Balance Scale (BBS) is used to assess the patient's ability to safely stabilize while performing certain tasks. It consists of a list of 14 items. Each item is evaluated through an ordinal scale ranging from 0 (lowest level of functionality) to 4 (highest level of functionality).

    Time frame: At baseline and post-training (up to 7 weeks)

  8. Modified Ashworth Scale (MAS)

    The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension).

    Time frame: At selection, baseline and post-training (up to 7 weeks)

  9. Location and level of pain

    The location and level of pain using the numeric rating scale (NRS) will be assessed. Each value is scored on a 0 to 10 scale, where 0 represents no pain and 10 represents the worst pain imaginable.

    Time frame: From baseline to post-training (up to 7 weeks)

  10. Borg Rating of Perceived Exertion

    The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion).

    Time frame: From baseline to post-training (up to 7 weeks)

  11. Functional Independence Measure (FIM)

    The Functional Independence Scale (FIM) is a widely used instrument to assess the patient's outcomes and progress in rehabilitation programs. It is an indicator of disability, which measures how much assistance the patient needs to perform activities of daily living . It includes 18 activities that are measured on a 7-level scale, with 1 being indicative of total assistance and 7 of complete independence.

    Time frame: At baseline and post-training (up to 7 weeks)

  12. Level of motivation

    Participants' perceptions on the level of motivation generated by the program with the ABLE Exoskeleton will be evaluated by the completion of a self-report questionnaire using a 7-point Likert scale. This questionnaire has been designed by the researchers.

    Time frame: At post-training (up to 7 weeks from baseline)

  13. Self-perceived impact on general health status

    Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton contributed to a change in their health. The questionnaire covers 7 categories (cardiovascular system, musculoskeletal pain, neuropathic pain, bladder and bowel, spasticity, and sleep quality) using a 7-point Likert scale to assess the change.

    Time frame: At post-training (up to 7 weeks)

  14. Psychosocial Impact of Assistive Devices Scale (PIADS) score

    The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience

    Time frame: At post-training (up to 7 weeks)

  15. Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score

    The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience

    Time frame: At post-training (up to 7 weeks)

07

Study locations

3 sites
  • Cefine Neurología (CEFINE)
    Culleredo, A Coruña 15174, Spain
  • Fundación Step by Step
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Centro Europeo de Neurociencias (CEN)
    Madrid, Madrid 28023, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Dec 2025, 5 months.

Of 298 interventional studies with no phase under Brain Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 3, 2025
StartActual
Jun 30, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 17, 2025
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050875
Lead sponsor
ABLE Human Motion S.L.
Collaborators
Centro Europeo de Neurociencias (CEN), Cefine Neurología (CEFINE), Fundación Step by Step (SBS)
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jun 30, 2025
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Last update
Jan 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion